Show metadata Hide metadata

(19)

(11)

2 316 326

(13)

(51)

IPC

A61K31/44(2006-01-01)

A61K31/17(2006-01-01)

A61K45/06(2006-01-01)

C07D213/56(2006-01-01)

C07C275/30(2006-01-01)

A61P35/00(2006-01-01)

(21) (22)

Application

2004120785/15, 2002-12-03

(24)

Start date

2002-12-03

(22)

Actual filing date

2002-12-03

(45)

Published

2008-02-10

(72)

Inventor

Vinsent Patrik U.Vud Dzhil Eh.Gibson NilDjuma ZhakZkhaj JifanKajre JudehjKarter Kristofer Eh.Louinger Timoti B.Mounehjkhehn Mehri-KehtrinNehjtiro RejnaRenik DzhouehlRidl' BerndSibli Robert N.Skott Uil'Jam Dzh.Smit Rodzher Eh.Trejl PamelaKhamfri Rejchel U.Khibner Barbara

(73)

Holder

Bajer Famehs'Jutikls Kopehrejshn

METHOD AND COMPOSITION FOR CANCER DISEASE TREATMENT, TOSYLATE AND PHARMACEUTICALLY ACCEPTABLE SALTS OF N-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)-N'-(4-(2-(N-METHYLCARBAMOYL)-4-PYRIDYLOXY)PHENYL)UREA Russian patent published in 2008 - IPC A61K31/44 A61K31/17 A61K45/06 C07D213/56 C07C275/30 A61P35/00

Abstract RU 2316326 C2

FIELD: medicine.

SUBSTANCE: invention relates to arylurea derivatives useful in treatment of raf kinase-mediated diseases such as cancer. Claimed composition contains therapeutically effective amount of raf kinase inhibitor, namely pharmaceutically acceptable salt of N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, in particular N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea tosylate.

EFFECT: agent for cancer treatment of increased activity.

11 cl, 5 dwg, 5 ex

Similar patents RU2316326C2

Title	Year	Author	Number
COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND IMANITIB DERIVATIVES FOR TREATMENT OR PREVENTION OF PROLIFERATIVE DISEASES	2006	Olland Lila Manli Pol U. Mestan Jurgen	RU2430727C2
COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR	2006	Manli Pol U. Lane Khajdi	RU2443418C2
COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR	2007	Manli Pol U.	RU2481840C2
COMBINATION OF (A) PHOSPHOINOSITIDE-3-KINASE INHIBITOR AND (B) Ras/Raf/Mek PATHAWAY MODULATOR	2009	Garsija-Ehcheverrija Karlos Mera Sove-Mishel' St'Juart Darrin Vi S'Jusan Frich Kristine Nejdzhel Tobi	RU2508110C2
SYNERGIC METHODS AND COMPOSITIONS FOR CANCER TREATMENT	2001	Li Frehnsis I.	RU2264217C2
ARYL- AND HETEROARYL-SUBSTITUTED HETEROCYCLIC DERIVATIVES OF UREA, METHOD FOR INHIBITION OF RAF KINASE ACTIVITY AND PHARMACEUTICAL COMPOSITION	1998	Vud Dzhil Eh. Dzhonson Dzhefri D'Jumehs Dzhekves Kajre Judehj Louinger Timoti Bruno Paul'Sen Khol'Ger Redmehn Aniko Ridl' Bernd Sibli Robert Skott Uil'Jam Dzh. Smit Rodzher Eh. Khatoum-Mokdad Kholija	RU2265597C2
PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR NEUROFIBROMATOSIS	2006	Manli Pol U.	RU2450814C2
N-[4-(HETEROARYLMETHYL)PHENYL]-HETEROARYLAMINES	1997	Vene Mark Gaston Mabir Dominik Zhan-P'Er Lakramp Zhan Fernan Arman San Zherar Sharl'	RU2190611C2
USING SMOOTHENED ANTAGONISTS FOR TREATING HEDGEHOG PATHWAY RELATED DISORDERS	2009	Marion Dorsh Dzhon Eh. Monakhan Majkl Patrik Morrissi Shifehn Pan' Dzhul'Et Uill'Jams	RU2519200C2
USE OF PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR TREATING SYSTEMIC MASTOCYTOSIS	2006	Olland Lejla Fabbro Doriano Mestan Jurgen Manli Pol U.	RU2445960C2

RU 2 316 326 C2

Authors

Vinsent Patrik U.

Vud Dzhil Eh.

Gibson Nil

Djuma Zhak

Zkhaj Jifan

Kajre Judehj

Karter Kristofer Eh.

Louinger Timoti B.

Mounehjkhehn Mehri-Kehtrin

Nehjtiro Rejna

Renik Dzhouehl

Ridl' Bernd

Sibli Robert N.

Skott Uil'Jam Dzh.

Smit Rodzher Eh.

Trejl Pamela

Khamfri Rejchel U.

Khibner Barbara

Dates

2008-02-10—Published

2002-12-03—Filed